Compare MDAI & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDAI | CCEL |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | United States | United States |
| Employees | 65 | N/A |
| Industry | Medical/Dental Instruments | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 41.8M |
| IPO Year | 2021 | 2022 |
| Metric | MDAI | CCEL |
|---|---|---|
| Price | $1.52 | $4.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $5.11 | N/A |
| AVG Volume (30 Days) | ★ 110.0K | 11.6K |
| Earning Date | 11-10-2026 | 10-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.88 | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | $19,650,000.00 | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $74.98 | N/A |
| P/E Ratio | ★ N/A | $22.04 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $1.18 | $2.72 |
| 52 Week High | $2.97 | $5.45 |
| Indicator | MDAI | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 54.73 |
| Support Level | $1.42 | $3.05 |
| Resistance Level | $1.48 | $5.45 |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 36.00 | 52.42 |
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.